Literature DB >> 8628317

Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles.

P Morcos1, N Thapar, N Tusneem, D Stacey, F Tamanoi.   

Abstract

Neurofibromin plays a critical role in the downregulation of Ras proteins in neurons and Schwann cells. Thus, the ability of neurofibromin to interact with Ras is crucial for its function, as mutations in NF1 that abolish this interaction fail to maintain function. To investigate the neurofibromin-Ras interaction in a systematic manner, we have carried out a yeast two-hybrid screen using a mutant of H-ras, H-rasD92K, defective for interaction with the GTPase-activated protein-related domain (GRD) of NF1. Two screens of a randomly mutagenized NF1-GRD library led to the identification of seven novel NF1 mutants. Characterization of the NF1-GRD mutants revealed that one class of mutants are allele specific for H-raSD92K. These mutants exhibit increased affinity for H-raSD92K and significantly reduced affinity for wild-type H-ras protein. Furthermore, they do not interact with another H-ras mutant defective for interaction with GTPase-activating proteins. Another class of mutants are high-affinity mutants which exhibit dramatically increased affinity for both wild-type and mutant forms of Ras. They also exhibit a striking ability to suppress the heat shock sensitive traits of activated RAS2G19v in yeast cells. Five mutations cluster within a region encompassing residues 1391 to 1436 (region II). Three NF1 patient mutations have previously been identified in this region. Two mutations that we identified occur in a region encompassing residues 1262 to 1276 (region I). Combining high-affinity mutations from both regions results in even greater affinity for Ras. These results demonstrate that two distinct regions of NF1-GRD are involved in the Ras interaction and that single amino acid changes can affect NF1's affinity for Ras.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8628317      PMCID: PMC231238          DOI: 10.1128/MCB.16.5.2496

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  37 in total

1.  Different kinetic properties of the two mutants, RAS2Ile152 and RAS2Val19, that suppress the CDC25 requirement in RAS/adenylate cyclase pathway in Saccharomyces cerevisiae.

Authors:  J B Créchet; P Poullet; J Camonis; M Jacquet; A Parmeggiani
Journal:  J Biol Chem       Date:  1990-01-25       Impact factor: 5.157

2.  Use of the Glu-Glu-Phe C-terminal epitope for rapid purification of the catalytic domain of normal and mutant ras GTPase-activating proteins.

Authors:  R H Skinner; S Bradley; A L Brown; N J Johnson; S Rhodes; D K Stammers; P N Lowe
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

3.  Synthesis and expression of a synthetic gene for the activated human c-Ha-ras protein.

Authors:  K Miura; Y Inoue; H Nakamori; S Iwai; E Ohtsuka; M Ikehara; S Noguchi; S Nishimura
Journal:  Jpn J Cancer Res       Date:  1986-01

4.  Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules.

Authors:  U Krengel; I Schlichting; A Scherer; R Schumann; M Frech; J John; W Kabsch; E F Pai; A Wittinghofer
Journal:  Cell       Date:  1990-08-10       Impact factor: 41.582

5.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

6.  Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.

Authors:  J B Gibbs; I S Sigal; M Poe; E M Scolnick
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

7.  The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins.

Authors:  R Ballester; D Marchuk; M Boguski; A Saulino; R Letcher; M Wigler; F Collins
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

8.  The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae.

Authors:  G F Xu; B Lin; K Tanaka; D Dunn; D Wood; R Gesteland; R White; R Weiss; F Tamanoi
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

9.  The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21.

Authors:  G A Martin; D Viskochil; G Bollag; P C McCabe; W J Crosier; H Haubruck; L Conroy; R Clark; P O'Connell; R M Cawthon
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

10.  Functional significance of lysine 1423 of neurofibromin and characterization of a second site suppressor which rescues mutations at this residue and suppresses RAS2Val-19-activated phenotypes.

Authors:  P Poullet; B Lin; K Esson; F Tamanoi
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

View more
  11 in total

1.  Computational insights of K1444N substitution in GAP-related domain of NF1 gene associated with neurofibromatosis type 1 disease: a molecular modeling and dynamics approach.

Authors:  Ashish Kumar Agrahari; Meghana Muskan; C George Priya Doss; R Siva; Hatem Zayed
Journal:  Metab Brain Dis       Date:  2018-05-27       Impact factor: 3.584

2.  Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.

Authors:  Juan Mo; Ji-Kang Chen; Corina Anastasaki; Jit Chatterjee; Yuan Pan; Suzanne M Scheaffer; Olivia Cobb; Michelle Monje; Lu Q Le; David H Gutmann
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 17.694

3.  p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression.

Authors:  Phillippe P Gonzalez; Jungeun Kim; Rui Pedro Galvao; Nichola Cruickshanks; Roger Abounader; Hui Zong
Journal:  Glia       Date:  2018-02-02       Impact factor: 7.452

4.  Structural analysis of the GAP-related domain from neurofibromin and its implications.

Authors:  K Scheffzek; M R Ahmadian; L Wiesmüller; W Kabsch; P Stege; F Schmitz; A Wittinghofer
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

5.  Rho3 of Saccharomyces cerevisiae, which regulates the actin cytoskeleton and exocytosis, is a GTPase which interacts with Myo2 and Exo70.

Authors:  N G Robinson; L Guo; J Imai; A Toh-E; Y Matsui; F Tamanoi
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

6.  Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.

Authors:  Juran Kato-Stankiewicz; Irina Hakimi; Gang Zhi; Jie Zhang; Ilya Serebriiskii; Lea Guo; Hironori Edamatsu; Hiroshi Koide; Sanjay Menon; Robert Eckl; Sukumar Sakamuri; Yingchun Lu; Quin-Zene Chen; Seema Agarwal; William R Baumbach; Erica A Golemis; Fuyuhiko Tamanoi; Vladimir Khazak
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

7.  Mutational Analysis of Ionizing Radiation Induced Neoplasms.

Authors:  Amy L Sherborne; Philip R Davidson; Katharine Yu; Alice O Nakamura; Mamunur Rashid; Jean L Nakamura
Journal:  Cell Rep       Date:  2015-09-03       Impact factor: 9.423

8.  NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome.

Authors:  Alessandro De Luca; Irene Bottillo; Anna Sarkozy; Claudio Carta; Cinzia Neri; Emanuele Bellacchio; Annalisa Schirinzi; Emanuela Conti; Giuseppe Zampino; Agatino Battaglia; Silvia Majore; Maria M Rinaldi; Massimo Carella; Bruno Marino; Antonio Pizzuti; Maria Cristina Digilio; Marco Tartaglia; Bruno Dallapiccola
Journal:  Am J Hum Genet       Date:  2005-10-26       Impact factor: 11.025

9.  The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies.

Authors:  Zenggang Li; Andrei A Ivanov; Rina Su; Valentina Gonzalez-Pecchi; Qi Qi; Songlin Liu; Philip Webber; Elizabeth McMillan; Lauren Rusnak; Cau Pham; Xiaoqian Chen; Xiulei Mo; Brian Revennaugh; Wei Zhou; Adam Marcus; Sahar Harati; Xiang Chen; Margaret A Johns; Michael A White; Carlos Moreno; Lee A D Cooper; Yuhong Du; Fadlo R Khuri; Haian Fu
Journal:  Nat Commun       Date:  2017-02-16       Impact factor: 14.919

10.  Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors.

Authors:  Ren-Yuan Bai; Dominic Esposito; Ada J Tam; Frank McCormick; Gregory J Riggins; D Wade Clapp; Verena Staedtke
Journal:  Gene Ther       Date:  2019-05-24       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.